Chengdu Olymvax Biopharmaceuticals Inc.’s Net Profit Dropped 75.4% in 2022

Chengdu Olymvax Biopharmaceuticals Inc. (成都欧林生物科技股份有限公司) (688319.SH) reported a net profit of 26.6 million yuan in 2022, down 75.4% year-on-year.

Meanwhile, the company posted 547.5 million yuan in revenue, up 12.4% year-on-year.

At the end of the reporting period, it had 1.5 billion yuan in total assets and 587 million yuan in total liabilities, with a liability-to-asset ratio of 39.7%.